Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5'-monophosphate response element modulator alpha in systemic lupus erythematosus

Table 1 Profiles of patients with SLE

Patient	Gender	Age (years)	SLEDAI	Medications
1	Female	23	8	Pred 30 mg/d
2	Female	20	6	Pred 20 mg/d
3	Male	38	7	Pred 20 mg/d
4	Female	21	3	None
5	Female	26	12	None
6	Female	28	12	Pred 40 mg/d
7	Female	35	4	HCQ 0.2 g/d
8	Female	19	2	None
9	Female	33	3	Pred 5 mg/d
10	Female	27	2	None
11	Female	32	15	Pred 40 mg/d, TG^c 30 mg/d
12	Female	22	4	HCQ 0.2 g/d
13	Female	20	3	Pred 5 mg/d
14	Female	22	10	Pred 30 mg/d, TG 30 mg/d
15	Female	25	0	None
16	Male	40	10	Pred 40 mg/d, HCQ 0.2 g/d
17	Female	30	16	Pred 50 mg/d, TG 30 mg/d
18	Female	26	2	HCQ 0.2 g/d
19	Female	20	8	None
20	Female	35	12	Pred 35 mg/d, HCQ 0.2 g/d

SLEDAI systemic lupus erythematosus, Pred prednisone, HCQ hydroxychloroquine, TG tripterygium glycoside

ISSN: 1868-7083